Achilles Therapeutics plc (ACHL) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
245 Hammersmith Road
London, W6 8PW
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 20 8154 4600
Website
Sector
Healthcare
Industry
Biotechnology
Employees
204
First IPO Date
March 31, 2021
| Name | Title | Pay | Year Born |
| Iraj Ali | Chief Executive Officer | 1.7M | 1975 |
| Daniel Carey Cazel Hood | General Counsel, Company Secretary & Director | 0 | N/A |
| Edward Samuel | Executive Vice President of Technical Operations | 0 | N/A |
| Lee Stern | Vice President of Investor Relations & External Communications | 0 | N/A |
| Robert Coutts | Chief Financial Officer & Director | 0 | 1984 |
| Tariq Ahmed | Executive Vice President of People | 0 | N/A |
| Sergio A. Quezada | Founder | 0 | 1976 |
| Julia Wilson | Head of Communications | 0 | N/A |
| Charles Swanton | Founder & Member of Scientific Advisory Board | 0 | 1972 |
| Mark William Lowdell | Founder & Member of Scientific Advisory Board | 0 | 1963 |
Achilles Therapeutics Plc is a clinical-stage biopharmaceutical company focused on immuno-oncology. The firm specializes in creating innovative precision T-cell therapies designed to combat a range of solid tumors. Its primary therapeutic candidates, both currently undergoing Phase I/IIa clinical trials, are CHIRON, aimed at advanced non-small cell lung cancer, and THETIS, targeting metastatic or recurrent melanoma. Beyond these, Achilles is also advancing its pipeline with treatments for head and neck squamous cell carcinoma, renal cell carcinoma, triple-negative breast cancer, and bladder cancer. Initially incorporated as Achilles TX Limited, the company officially adopted the name Achilles Therapeutics Plc in February 2021. Established in 2016, its corporate headquarters are situated in London, United Kingdom.